Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Yousef Zakharia(University of Iowa), Youcef M. Rustum(University of Iowa), Jessica C. Sieren(University of Iowa), Umang Swami(University of Utah), Sarah L. Mott(University of Iowa), K.D. Zamba(University of Iowa), Ryan J. Reis(University of Iowa), Rohan Garje(Baptist Hospital of Miami), Aseel O. Rataan(American Association of Colleges of Pharmacy), Bilal Rahim(University of Iowa), Srija Manchkanti(University of Iowa), Matthew R. Kroll(University of Iowa), Aliasger K. Salem(University of Iowa)
Cited by 1
Related Papers
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274
Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study
|BJOG An International Journal of Obstetrics & Gynaecology|1995|215
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190